[Correspondence] Intravenous versus subcutaneous immunoglobulin – Authors' reply

We thank Ravi Uniyal and colleagues for their comments on our results from the PATH trial1 on subcutaneous immunoglobulin (SCIg) for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). They express concern about the relapse rates in the treatment groups and hypothesise the cause being the pharmacokinetics of SCIg.

Source: Lancet Neurology - April 13, 2018 Category: Neurology Authors: Ivo N van Schaik, Orell Mielke, PATH study group Tags: Correspondence Source Type: research